- OncoGenex (click here for full OGXI research page) presented 9/20 at UBS conference, click here for all upcoming biotech events and links to my notes.
- Quick notes:
- Cash sufficient to middle of 2014
- metastatic bladder cancer randomized phase 2 trial will start by end of 2011, take about 18 months to complete enrollment, and have data in the beginning of 2014.
- Prostate cancer is "crowded field", but is the second leading cause of cancer death among men (justifying custirsen program)
RSS Feed
